We continue our series of posts inspired by Drug Hunter’s “Molecules of the Month” (drughunter.com)!

A recently highlighted molecule by Drug Hunter is tovorafenib (BIIB-024/TAK-580/MLN 2480) — an orally active, CNS-penetrant selective inhibitor of RAF kinase, which is now in Phase III trials for treating pediatric low-grade glioma (pLGG).

Chemspace offers a selected set of analogs of this drug candidate from our In-Stock and Make-On-Demand catalogs. Exploring the vast chemical space could lead to unexpected insights and promising results!

Follow the link to uncover the molecules we have prepared for you!

Pediatric LGG is the most common brain tumor in children, accounting for approximately 20% of all childhood CNS tumors. These malignancies are characterized by slow growth and relatively good prognosis, with very high 5-year survival rates. However, a subset of pLGGs progresses to high-grade gliomas, which have a much poorer prognosis. Tovorafenib acts as an RAF inhibitor that has shown promise in treating this disease. RAF inhibitors block the activity of the RAS/RAF/MEK/ERK signaling pathway, which is frequently mutated across pLGG. During preclinical studies, tovorafenib has been shown to inhibit the growth of glioma cells and prolong survival in animal models.

Go to chem-space.com/search to find In-Stock and Make-on-Demand molecules of your interest!